Table 4.
Overall surgical and clinical outcomes and comparisons based on POD1 GH cutoff of 1.55ng/mL.
| Overall (n = 94) | POD1 GH <1.55ng/mL (n = 44) | POD1 GH ≥1.55ng/mL (n = 50) | p-value | |
|---|---|---|---|---|
| Surgical outcomes | No. (%) | No. (%) | No. (%) | |
| Median imaging follow-up (months) | 16 (4.8-38) | 18 (IQR 8.8-40) | 15 (IQR 3.4-37) | – |
| Gross total resection | 42 (63) | 24 (54.5) | 18 (36) | 0.003 |
| Subtotal resection | 25 (37) | 5 (11) | 20 (40) | 0.003 |
| Recurrence after GTR | 3 (3) | 2 (4.5) | 1 (2) | 0.555 |
| Progression after STR | 2 (2) | 1 (2) | 1 (2) | 0.824 |
| Clinical outcomes | No. %) | No. (%) | No. (%) | |
| Median clinical follow-up (months) | 17 (4.6-41) | 17 (IQR 5.5-44) | 16 (IQR 3.4-38) | – |
| Hormonal remission | 77 (82) | 40 (91) | 37 (74) | 0.034 |
| Time to remission (months) | 8 (IQR 1-8.5) | 3 (IQR 1-5) | 4 (IQR 1.5-10.5) | – |
| Additional treatment | 24 (26) | 4 (9) | 30 (60) | 0.001 |
| Medications | 21 (22) | 2 (4.5) | 19 (38) | <0.001 |
| Stereotactic radiosurgery | 8 (9) | 3 (7) | 5 (10) | 0.581 |
| Radiation therapy | 2 (2) | 1 (2) | 1 (2) | 0.927 |
| Additional surgical resection | 1 (1) | 1 (2) | 0 (0) | 0.284 |
| Postoperative endocrine labs | Median (IQR) | Median (IQR) | Median (IQR) | |
| Most recent follow-up IGF-1 (ng/ml) (n=93) | 190 (138.5-274) | 194 (139-235) | 187 (137-340) | 0.836 |
| Most recent follow-up corrected IGF-1 (%ULN) (n=71) | 62.8 (45-80) | 60.7 (43.8-78.7) | 63 (46.6-91.9) | 1.00 |
| Apex follow-up IGF-1 (ng/ml) (n=93) | 238 (175-370.5) | 226 (165-316) | 260 (182-433) | 0.097 |
| Apex follow-up corrected IGF-1 (%ULN) (n=71) |
80.4 (64-114) | 74.2 (61.6-97.9) | 91.8 (64.1-162) | 0.157 |